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O-GlcNAcylation is a posttranslational modification that adds O-linked β-N-acetylglucosamine (O-GlcNAc) to serine or threonine
residues of many proteins. This protein modification interacts with key cellular pathways involved in transcription, translation, and
proteostasis. Although ubiquitous throughout the body, O-GlcNAc is particularly abundant in the brain, and various proteins
commonly found at synapses are O-GlcNAcylated. Recent studies have demonstrated that the modulation of O-GlcNAc in the brain
alters synaptic and neuronal functions. Furthermore, altered brain O-GlcNAcylation is associated with either the etiology or
pathology of numerous neurodegenerative diseases, while the manipulation of O-GlcNAc exerts neuroprotective effects against
these diseases. Although the detailed molecular mechanisms underlying the functional roles of O-GlcNAcylation in the brain remain
unclear, O-GlcNAcylation is critical for regulating diverse neural functions, and its levels change during normal and pathological
aging. In this review, we will highlight the functional importance of O-GlcNAcylation in the brain and neurodegenerative diseases.
Experimental & Molecular Medicine; https://doi.org/10.1038/s12276-021-00709-5
INTRODUCTION
O-GlcNAcylation, which attaches O-linked β-N-acetylglucosamine
(O-GlcNAc) moieties to either serine or threonine residues of
intracellular proteins, is a posttranslational modification that
critically regulates essential cellular functions1–7. Notably, this
modification is catalyzed by only two enzymes, O-GlcNAc
transferase (OGT) and O-GlcNAcase (OGA). OGT catalyzes the
addition of O-GlcNAc to the hydroxyl groups of serine/threonine
residues of nucleocytoplasmic proteins, whereas OGA removes
the modification from proteins (Fig. 1)1,3,4,8,9. O-GlcNAcylation
occurs in various cellular locations, such as the nucleus, cytosol,
and cellular organelles, including mitochondria, the cytoskeleton,
and the endoplasmic reticulum10. O-GlcNAcylation by OGT utilizes
uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) as a
precursor molecule, which is synthesized by the hexosamine
biosynthesis pathway (HBP) that is pivotal for the cellular
metabolism of amino acids, lipids, and nucleotides in the cell
(Fig. 1)1. In the HBP, glucose is first phosphorylated by hexokinase
(HK) and converted to glucose-6-phosphate (G-6P). Next, G-6P is
transformed into fructose-6-phosphate (F-6P) by phosphoglucose
isomerase (GPI). Then, glutamine:fructose-6-phosphate amino-
transferase (GFAT), a rate-limiting enzyme of HBP, catalyzes F-6P
and glutamine into glucosamine-6-phosphate (GlcN-6P). With
acetyl-CoA, GlcN-6P is further catalyzed by glucosamine-
phosphate N-acetyltransferase (GNA1) and turns into N-acetylglu-
cosamine-6-phosphate (GlcNAc-6P). Further isomerization by
GlcNAc phosphomutase (PGM3) produces N-acetylglucosamine-
1-phosphate (GlcNAc-1P). Finally, with uridine triphosphate (UTP),
UDP-GlcNAc, and pyrophosphate (PPi) are produced by UDP-
GlcNAc pyrophosphorylase (UAP1) (Fig. 1)2,11. Notably, since
O-GlcNAcylation occurs on serine/threonine residues of proteins,
the O-GlcNAcylation site can also be phosphorylated, and there
could be extensive crosstalk between O-GlcNAcylation and
phosphorylation3,8,12. Hence, it is conceivable that O-GlcNAcyla-
tion, through its competitive interplay with phosphorylation, could
critically affect a variety of cellular signaling pathways by
dynamically modulating protein activities8,13.
Mounting evidence has shown that O-GlcNAcylation regulates
essential cellular processes such as gene expression, signal
transduction, cell cycle, nutrient sensing, protein homeostasis,
and cellular responses to diverse stress conditions (Fig. 1)13–18. In
addition, altered and abnormal O-GlcNAcylation is frequently
observed in multiple disease conditions, including cancer,
cardiac hypertrophy, and type II diabetes19–23, supporting the
notion that O-GlcNAcylation is implicated not only in maintain-
ing normal cellular functions but also in the pathological
processes of human diseases. Notably, among bodily organs,
O-GlcNAcylation is the most abundant in the brain10. Further-
more, two related enzymes, OGT and OGA, show high expression
and activity in the brain24,25. These findings strengthen the
emerging notion that O-GlcNAcylation plays an important role in
various neural functions. Therefore, in this review, we will focus
on the importance of O-GlcNAcylation in neural functions and
neurodegenerative diseases.
O-GLCNACYLATION IN THE BRAIN
The physiological importance of O-GlcNAcylation in the brain is
reflected by the fact that both OGT and OGA are indispensable
for neuronal survival. Genetic deletion of OGT caused embryonic
stem cell lethality, while deletion of OGA led to perinatal
lethality26–28. In addition, although it is still not clear how these
changes occur, neuron-specific elimination of either OGT or OGA
results in severe structural abnormalities in the nervous system,
which seems to be caused either by neurodevelopmental defects
or premature neurodegeneration29–32. More importantly, recent
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studies are beginning to show that O-GlcNAcylation is crucial not
only for neuronal survival but also for neuronal and synaptic
function in the mature brain. O-GlcNAcylation in the brain is
highly enriched, especially at synapses. OGA and OGT are
significantly active at functional synapses, leading to extensive
O-GlcNAc modification of proteins in nerve terminals33. More-
over, many synaptic and neuronal proteins important for
structure and function, such as bassoon, synapsin I, piccolo,
synaptopodin, GluA2, calcium/calmodulin-dependent kinases II
(CaMKII), CaMKIV, and cyclic adenosine monophosphate (AMP)-
response element-binding protein (CREB), are modified by
O-GlcNAcylation (Fig. 2)15,34–38. O-GlcNAcylation of these pro-
teins was found to critically regulate the functional properties of
neurons in multiple neural circuits.
When O-GlcNAc was acutely increased by an OGA inhibitor,
thiamet-G (TMG), neuronal excitability, and excitatory synaptic
transmission of hippocampal neurons were suppressed. A transient
enhancement of O-GlcNAcylation elevated the amplitude of the
voltage-dependent potassium channel current and the expression of
hyperpolarization-activated cyclic nucleotide-gated (HCN) channels
and reduced the size of voltage-gated sodium channels39. This
suppression of neuronal excitability by O-GlcNAcylation in multiple
cation channels clearly demonstrates the ability of O-GlcNAc
modification to regulate neuronal function. Agouti-related protein
(AgRP)-expressing neurons in the hypothalamus showed enriched
OGT expression, and selective knockout of OGT in these AgRP
neurons inhibited their spontaneous firing activity due to the
defective action of the voltage-gated potassium channel Kcnq3
(Kv7.3) by loss of O-GlcNAc modification in this potassium channel40.
Forebrain excitatory neuron-specific deletion of OGT by using mice
expressing a tamoxifen-inducible Cre recombinase under the control
of the CaMKIIα promoter also promoted hyperphagia-dependent
obesity by attenuating excitatory input to the paraventricular nucleus
(PVN) neurons in the hypothalamus41. Consistent with this finding,
OGT is enriched in the postsynaptic density of excitatory synapses,


































Fig. 1 O-GlcNAcylation and its regulation of various cellular processes. O-GlcNAcylation is a posttranslational modification that attaches
O-GlcNAc moieties to serine or threonine residues of cellular proteins. O-GlcNAcylation can regulate important cellular processes such as gene



















Fig. 2 Neuronal and synaptic proteins modified by O-GlcNAcylation. Various neuronal and synaptic proteins, including bassoon, piccolo,
synapsin I, GluA2, CaMKII, CaMKIV, and CREB, are modified by O-GlcNAcylation. These modifications critically regulate neuronal and synaptic
properties.
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reduced the number of mature excitatory synapses by regulating the
synaptic expression of α-amino-3-hydroxy-5-methyl-4-isoxazolepro-
pionic acid (AMPA) receptors42. Dopaminergic neuron-specific
elimination of OGT caused early loss of axonal arborization and
premature neurodegeneration, whereas enhancement of
O-GlcNAcylation by knocking out OGA in dopamine neurons did
not negatively affect neuronal structures. Interestingly, these
dopamine neuron-specific OGA knockout mice exhibited enhanced
dopamine release at dopamine terminals in the striatum, suggesting
the potential role of O-GlcNAcylation in modulating the synaptic
release machinery32. These studies collectively indicate that neuronal
O-GlcNAcylation significantly regulates not only the survival or
maintenance of neurons but also the physiological functions of
synapses and neurons in the brain. Given the diverse roles played by
O-GlcNAcylation in key cellular processes, much needs to be
identified with respect to O-GlcNAcylated neuronal proteins, their
O-GlcNAcylation sites, and the brain-specific signaling mechanisms
selectively affected by O-GlcNAc modification.
O-GLCNACYLATION AND NEURODEGENERATIVE DISEASES
Aging
Considering the critical role of O-GlcNAcylation in regulating
synaptic and neuronal functions, it is reasonable to assume that
the alteration of O-GlcNAc levels during aging could exert
deleterious effects on numerous neural functions in the brain.
Several reports have shown that the abundance of
O-GlcNAcylation changes depending on aging conditions43–48. In
the hippocampus of aged mice, both OGT expression and the
level of O-GlcNAcylation were decreased compared with those in
young mice, and this loss of O-GlcNAcylation by age impaired
cognitive function44. Age-dependent loss of O-GlcNAcylation in
neural stem cells (NCS) is correlated with reduced neurogenesis
and increased gliogenesis in the hippocampus47. Notably,
decreased O-GlcNAcylation in the NSCs of young mice by
conditional knockout of OGT led to a reduction in adult
neurogenesis and impaired hippocampal-dependent learning
and memory47. The relationship between O-GlcNAcylation and
aging was also found in invertebrate organisms such as
Caenorhabditis elegans. The oga-1 C. elegans mutant showed
altered gene expression compared with the wild-type, and these
differentially expressed genes were largely associated with the
aging pathway and lifespan49. Moreover, modulating O-GlcNAc
levels by manipulating HBP revealed a protective effect on the
aging and lifespan of C. elegans. Lifespan was significantly
increased in the gfat-1 gain-of-function mutants, and supplemen-
tation with GlcNAc was sufficient to extend the lifespan by
alleviating proteotoxicity and improving protein quality control50.
Supplementation with glucosamine (GlcN) also resulted in an
extended lifespan in both nematodes and aged mice51. Collec-
tively, these findings identify a critical role of O-GlcNAcylation and
related pathways in aging and lifespan.
Moreover, according to recent studies, alterations of
O-GlcNAcylation in various neuronal proteins are found in aging-
related neurodegenerative diseases, including Alzheimer’s disease
(AD) and Parkinson’s disease (PD)52,53. Numerous proteins asso-
ciated with neurogenerative diseases appear to be O-GlcNAcy-
lated, and their O-GlcNAcylation status can change the progression
of disease pathology (Table 1)8,54,55. Tau protein, one of the best-
known hallmarks of AD, is O-GlcNAcylated in the brain56–58. It has
been shown that the O-GlcNAcylation of tau protein mitigates
pathological aggregates of tau and, as a consequence, ameliorates
cellular toxicity caused by aggregated tau59. Thus, elucidation of
the alterations of O-GlcNAcylation in neurodegenerative diseases
not only provides a more comprehensive view of the role of
O-GlcNAcylation in the brain but also is vital to the identification of
novel therapeutic targets and therapies against currently untrea-
table neurodegenerative diseases such as AD.
Alzheimer’s disease
Alzheimer’s disease (AD) is the most common neurodegenerative
disease and is characterized by progressive mental deterioration.
Symptoms start with mild memory deficits and mood changes
and progress to severe cognitive impairment and difficulties in
swallowing and urination, eventually resulting in death60.
Recently, researchers found that the O-GlcNAc level is 22 to
50% lower in AD patients than in healthy controls57,61–63. As such,
it is plausible that O-GlcNAcylation is associated with the
pathogenesis and/or progression of AD pathology. In addition
to amyloid-beta, tau protein has been shown to play a major role
in the pathology of AD64,65. Tau is a microtubule-associated
protein that modulates the stability of the neuronal cytoskeleton,
and the activity of tau protein, like many other proteins, is highly
regulated by phosphorylation. In the AD brain, tau is abnormally
hyperphosphorylated and then accumulates. This accumulation
of hyperphosphorylated tau eventually forms neurofibrillary
tangles (NFTs) that induce significant cellular toxicity64,65.
Importantly, tau protein is extensively O-GlcNAcylated56,57, and
several studies have revealed that O-GlcNAcylation of tau can
effectively reduce tauopathy. Treatment with an OGA inhibitor,
thiamet-G, in PC-12 cells expressing tau protein substantially
diminished tau phosphorylation at Ser396 and Thr231, the initial
priming phosphorylation sites of pathological tau, and this result
was also replicated in the rat brain after thiamet-G treatment
in vivo66. Among AD mouse models, the JNPL3 mouse is a
transgenic mouse model that overexpresses mutant human
P301L tau. This mouse develops neurofibrillary tangles, gliosis,
and neurodegeneration in an age-dependent manner due to tau
hyperphosphorylation67. When the JNPL3 mice were treated with
thiamet-G, the phosphorylated tau at Ser202 and Thr205 was
remarkably reduced in the brain. Moreover, this decrease in
pathological tau phosphorylation led to the attenuation of NFT
formation and neuronal death, suggesting a neuroprotective
effect of O-GlcNAcylation in the AD brain59.
Amyloid-β (Aβ) plaques are another hallmark of AD. Aβ is a
peptide whose toxic oligomeric form is widely found in the brains
of AD patients68. The 5xFAD mouse is a well-studied AD model
overexpressing human mutant Aβ precursor protein and shows
severe amyloid pathology, including elevated extracellular Aβ
plaques. When 5xFAD mice were treated with an OGA inhibitor,
the number of Aβ plaques was remarkably reduced compared to
that in vehicle-treated mice69. This reduction in Aβ plaques was
caused by the attenuated activity of γ-secretase, a critical enzyme
for Aβ generation. Furthermore, the activity of γ-secretase was
attenuated through O-GlcNAcylation at the Ser708 residue of
nicastrin (NCT), which is an essential component of the γ-secretase
complex and acts as a substrate receptor69,70. From the above, it is
apparent that in addition to the regulation of NFT formation,
O-GlcNAcylation might be critical for the modulation of γ-secretase
activity and the resulting Aβ production. The reactivity of microglia
and astrocytes was also significantly reduced by OGA inhibition,
and this reduction in amyloid pathology resulted in the recovery of
impaired memory function in 5xFAD mice69. Genetically increased
O-GlcNAc levels due to insufficient OGA also recovered impaired
cognitive function in 5xFAD mice (5xFAD;OGAfl/+)63. The amount of
Aβ in 5xFAD;OGAfl/+ mice was significantly reduced compared
with that in 5xFAD mice, resulting in attenuation of neuronal
death. This alleviation of pathology in 5xFAD;OGAfl/+ mice, in turn,
markedly restored cognitive function63. Given that the elevation of
O-GlcNAcylation does not cause any harmful effects on the
structure and function of neurons32,59, it is conceivable that
increasing O-GlcNAcylation would have a neuroprotective effect
against AD with minimal side effects. Recently, selective and small-
molecule OGA inhibitors such as MK-8719 and ASN120290
(previously known as ASN-561) have entered early clinical trials
for the treatment of progressive supranuclear palsy (PSP)71.
Moreover, LY3372689, another OGA inhibitor, is being developed
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for the treatment of tauopathies, including AD. Hopefully, the
results from these clinical trials may be utilized to justify whether
brain-permeable OGA inhibitors can be pursued for further clinical
development against AD.
Huntington’s disease
Huntington’s disease (HD) is a rare, inherited neurodegenerative
disease that is characterized by progressive neurodegeneration,
motor impairment, and cognitive dysfunction72,73. The main cause
of HD is a mutation of the huntingtin (HTT) gene coding the
huntingtin protein (HTT). Originally, the HTT gene contains up to
34 glutamine-coding (CAG) repeats. By mutations, this repeat
expands to polyglutamine repeats and causes misfolding of the
huntingtin protein74. This abnormally folded protein is prone to
aggregate, readily forming oligomers. These oligomers are seeds
for larger inclusions and pathogenic mutant huntingtin (mHTT)
fibrils74. Functionally, these mHTT fibrils and aggregates interrupt
synaptic transmission, mitochondrial axonal transport, and gene
transcription74. To date, the relationship between O-GlcNAcylation
and HD has been unclear. Interestingly, however, HTT protein and
huntingtin-interacting protein 1-related protein (HIP1R) appear to
be O-GlcNAc-modified, indicating that HTT protein could be
functionally regulated by O-GlcNAcylation32,75. When the HTT
protein construct with polyglutamine repeats was coexpressed
with OGA in Neuro2A cells (murine neuroblastoma cell line), the
number of transfected cells with mutant huntingtin aggregates
was significantly reduced. Coexpression of the OGA constructs
also led to a significant reduction in cell death mediated by mHTT
aggregation76. In contrast to the findings in cases of AD, these
results support the possibility that lowering O-GlcNAcylation
levels can mitigate the aggregation and cellular toxicity of the
mHTT protein.
In HD mouse models, distortion of the nuclear membrane and
disrupted nucleocytoplasmic transport were also observed77.
Nucleoporin (NUP) is a component of the nuclear pore complex
that is required for selective transport across the nuclear pore.
Notably, mislocalization of this NUP was found in HD mouse models.
R6/2 and zQ175 mice are HD mouse models expressing human
mHTT with expanded CAG repeats78,79. In R6/2 mice that develop
progressive motor and cognitive deficits as early as 6-8 weeks of age,
NUP62, which is important for controlling nuclear pore permeability
and selective transport, formed intranuclear inclusions and was
colocalized with mHTT aggregates80. Consistent with this finding,
intracellular inclusions formed by NUP88 were found and colocalized
with mHTT aggregates in zQ175 mice80. This NUP mislocalization and
pathology were also observed in postmortem human brains from HD
patients80. Intriguingly, NUP is heavily O-GlcNAcylated, and its
O-GlcNAcylation appears to be critical for nuclear pore integrity
and selective filtration81. Strengthening this result, there was a
reduction in O-GlcNAcylation in zQ175 mice, and treatment of
primary cortical neurons transfected with HTT 82Q with an OGA
inhibitor markedly reduced cell death, indicating that elevation of
O-GlcNAc levels could restore nucleocytoplasmic trafficking80. On the
basis of these observations, NUP mislocalization in HD pathology is
likely linked to altered levels of O-GlcNAcylation. Thus, it is
increasingly evident that O-GlcNAcylation may be related to HD
pathology by modulating mHTT aggregation and nucleocytoplasmic
transport. Further elucidation of the exact role of O-GlcNAcylation in
HD pathology will lead to a better understanding of the molecular
etiology and pathophysiology of HD.
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s
disease, is a neurodegenerative motor neuron disease that causes
the degeneration of both lower and upper motor neurons in the
motor cortex, brain stem nuclei, and anterior horn of the spinal
cord82–84. This loss of motor neurons results in focal limbic muscle
weakness and progresses to respiratory failure, limiting survival
to 2–4 years after disease onset82,83. Nevertheless, the exact
mechanism of motor neuron degeneration remains incompletely
understood. Several factors, such as genetic mutation, abnormal
neurofilament function, oxidative stress, and inflammation, are
considered the main causes of ALS84. In ALS, 90% of cases are
classified as sporadic ALS, and the remaining 10% of cases
are familial ALS with dominantly inherited autosomal mutations in
SOD1 (superoxide dismutase 1), TDP-43 (TAR DNA-binding protein
43), FUS (fused in sarcoma/translated in liposarcoma), and C9orf72
(chromosome 9 open reading frame 72)83. According to recent
studies of ALS, O-GlcNAcylation can play a neuroprotective role
against ALS pathology. It was reported that the abundance of
O-GlcNAcylation in mutant SOD1-overexpressing mice was
significantly reduced in the motor neurons of the spinal cord
compared with that of wild-type mice85. Interestingly, hyperpho-
sphorylated neurofilaments (NFs) and their aggregation are
observed in ALS pathology86,87, and this neurofilament is modified
by O-GlcNAc32,88. Consistent with these findings, O-GlcNAcylation
of neurofilaments remarkably decreased in the ALS rat model
overexpressing mutant SOD1, potentially indicating the disruption
of O-GlcNAcylation in ALS pathology89. Considering the crosstalk
with phosphorylation, O-GlcNAcylation may suppress excessive
phosphorylation of neurofilaments and concomitantly alleviate
ALS pathology.
In addition, the elevation of oxidative stress is one of the
primary factors leading to the degeneration of motor neurons in
ALS83,84. Nonselenocysteine-containing phospholipid hydroper-
oxide glutathione peroxidase (NPGPx) is an oxidative stress sensor
and transmitter that modulates protein activity by shuffling
disulfide bonds90. Notably, NPGPx knockout mice showed ALS-like
phenotypes such as paralysis, denervation of neuromuscular
junctions, and motor neuron loss. Importantly, these mice
displayed dysregulation of O-GlcNAc levels and ROS accumula-
tion, consequently causing motor neuron death. However, this
loss of motor neurons was recovered by elevating O-GlcNAc
levels with an OGA inhibitor91. These results suggest that
O-GlcNAcylation can modulate ALS pathology by reducing ROS
accumulation. TDP-43 protein pathology is also a hallmark of ALS.
TDP-43 is an RNA/DNA-binding protein and acts as a regulator of
transcription, mRNA stability, and transport92. The excessive
accumulation of TDP-43 in the cytoplasm produces inclusion
bodies, which induce cellular toxicity by abnormal protein/RNA
interactions84,93. A recent study reported that the O-GlcNAcylation
of endogenous TDP-43 was found in human SH-SY5Y neuroblas-
toma cells, and mass spectrometry analysis further detected
O-GlcNAcylation at the T199 and T233 sites of TDP-4394. As in the
aforementioned cases, coexpression of OGT with an ALS-linked
mutant of TDP-43 significantly suppressed abnormal TDP-43
aggregation and related cellular toxicity94. Together, these studies
indicate a critical role of O-GlcNAcylation in modulating ALS
pathology by inhibiting excessive phosphorylation and protein
aggregation and reducing ROS accumulation. The molecular
mechanisms underlying the role of O-GlcNAcylation in ALS
pathology need to be further elucidated.
Parkinson’s disease
Parkinson’s disease (PD) is the second most common neurode-
generative disease after AD. PD patients generally develop motor
symptoms, including rigidity, bradykinesia, and postural instabil-
ity95–98. However, alongside these motor symptoms, they also
experience nonmotor symptoms such as sleep disruption,
depression, and even cognitive decline years before the diagnosis
of PD98,99. The loss of dopaminergic neurons in the midbrain and
the functional disruption of the basal ganglia circuitry are the key
features of PD pathophysiology96,100. Among pathological mar-
kers of the disease, Lewy bodies (LBs), composed of an abnormal
aggregation of proteins, are a well-known pathological hallmark
of PD that can induce neuronal toxicity, and α-synuclein is the
B.E. Lee et al.
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major component of LB inclusions101,102. α-Synuclein, contribut-
ing a large proportion of PD pathology, is expressed abundantly
in the brain and is primarily located in presynaptic terminals and
synaptic vesicles102,103. Although the function of α-synuclein is
still unclear, α-synuclein is known to regulate the mobility,
release, and maintenance of synaptic vesicles102,103. As with other
aggregation-prone proteins, α-synuclein phosphorylation can
induce abnormal aggregation, and this aggregation, in turn, is
capable of significantly disturbing cellular structure and function,
which eventually causes neuronal death104. Notably, α-synuclein
is also O-GlcNAc modified104,105. When α-synuclein was
O-GlcNAcylated in a site-specific manner, the abnormal aggrega-
tion of α-synuclein by phosphorylation was markedly diminished,
resulting in alleviated neurotoxicity in cultured neurons106–108. In
these experiments, α-synuclein containing O-GlcNAc at T72 did
not form any aggregates or oligomers and inhibited phosphor-
ylation at S87 and S129, which has been found to be closely
related to α-synuclein aggregation in PD pathology. In addition,
treatment with O-GlcNAcylated α-synuclein in cultured neurons
reduced neuronal death106. Despite its variable impact depend-
ing on the specific O-GlcNAcylation sites, O-GlcNAcylated α-
synuclein largely showed an inhibitory effect on aggregation.
The O-GlcNAcylation of α-synuclein at T72, T75, and T81
remarkably inhibited or attenuated α-synuclein aggregation
compared to that of unmodified α-synuclein, and triple
O-GlcNAcylation of α-synuclein at all of these sites completely
blocked aggregation107. In a similar vein, the elevation of
O-GlcNAc in neuroblastoma cells by OGA inhibition reduced the
uptake of α-synuclein preformed fibrils (PFFs) without interrupt-
ing the normal endocytosis capacity109. Taken together, these
findings strongly indicate that O-GlcNAcylation of α-synuclein can
attenuate pathological aggregation of α-synuclein and α-synu-
clein-mediated neurotoxicity in vitro.
Recent findings from our group also demonstrated that
O-GlcNAcylation plays an important role in the function, survival,
and degeneration of dopamine neurons in vivo in a mouse model of
PD32. In our study, dopaminergic neuron-specific OGT knockout
mice exhibited a significant loss of dopamine neurons in the
midbrain and premature death at ~8 to 15 weeks of age. In contrast,
selective enhancement of O-GlcNAcylation in dopamine neurons did
not negatively impact neuronal structures or survival. Rather, it
facilitated synaptic transmission at dopamine synapses in mice with
OGA conditional knockout32. These results indicate that
O-GlcNAcylation is essential for neuronal survival and function in
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Fig. 3 O-GlcNAcylation and its neuroprotective role in neurons. Key etiological proteins of neurodegenerative diseases, such as tau,
α-synuclein, HTT, and neurofilament, can be directly O-GlcNAcylated, and proteins, including amyloid-beta and TDP-43, are indirectly affected
by O-GlcNAcylation. In neurodegenerative diseases, altered O-GlcNAcylation is detected, and this abnormal O-GlcNAc status and subsequent
excessive phosphorylation can cause pathological protein aggregation, resulting in cellular toxicity in neurons.
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dopamine neurons. More interestingly, when we generated a mouse
model of PD by overexpressing mutant α-synuclein in the midbrain
of mice with OGA conditional knockout, the elevated
O-GlcNAcylation dramatically alleviated PD pathology in dopamine
neurons, including abnormal aggregation of α-synuclein and
neuronal death. As a functional consequence of these changes,
impaired dopamine release and motor behaviors observed in PD
model mice were significantly recovered by enhanced
O-GlcNAcylation32. Together, the elevation of O-GlcNAc levels
in vivo can alleviate PD pathology and related physiological
symptoms, possibly by inhibiting the pathological aggregation of
α-synuclein. Given that both genetic and pharmacological elevation
of O-GlcNAc did not cause any harmful effects on brain function and
general health in mice32, it may be clinically promising to develop
PD therapies focusing on O-GlcNAcylation. More research should be
conducted to identify molecular targets of O-GlcNAcylation in
dopamine neurons and their pathophysiological roles in PD.
CONCLUSION AND PERSPECTIVES
O-GlcNAcylation critically contributes to various cellular processes,
including transcription, translation, signaling cascades, and
protein homeostasis, in a multitude of cell types, and more than
5000 human proteins have been identified as O-GlcNAcylated
proteins thus far10. Notably, recent studies on O-GlcNAcylation
have begun to emphasize the importance of O-GlcNAcylation in
the central nervous system. There is undoubtedly evidence
indicating a pivotal role of O-GlcNAcylation in the brain. First,
O-GlcNAc modification is most abundant in the brain among
various organs. Second, numerous proteins enriched in and
important for functional synapses are O-GlcNAcylated. Most
importantly, accumulating studies have demonstrated that
genetic or pharmacological manipulation of O-GlcNAcylation
remarkably alters neuronal and synaptic functions in the brain.
Moreover, the critical role of O-GlcNAcylation is not limited to the
normal, healthy brain. Several proteins known as key etiological
factors in neurodegenerative diseases, including tau, amyloid-beta
precursor protein (APP), α-synuclein, and HTT, are O-GlcNAcylated.
In addition, the status of O-GlcNAcylation in these proteins is
associated with many pathological conditions in neurodegenera-
tive diseases. In experimental studies, altering O-GlcNAc levels in
the brain or cultured neurons reduces aberrant protein aggrega-
tion, which is a common hallmark of neurodegenerative diseases.
Moreover, the manipulation of O-GlcNAcylation (mostly enhance-
ment) in neurodegenerative disease-related proteins mitigates
neurotoxicity, functional impairment, and neuronal death, strongly
suggesting the neuroprotective effect of O-GlcNAcylation (Fig. 3).
It is important to note that, in most cases, either genetic or
pharmacological manipulation of O-GlcNAc levels does not lead to
any deleterious effects on the structure and function of neurons in
the brain; instead, it specifically suppresses neurodegenerative
disease-related pathology in animal models. Thus, it is worth
pursuing O-GlcNAcylation as a therapeutic target for many
neurodegenerative diseases, such as AD and PD.
However, caution should be exercised because O-GlcNAcylation
is a dynamic modification that reversibly interacts with other
posttranslational modifications, including phosphorylation, ubiqui-
tylation, acetylation, and methylation, and causes complicated
modulation of diverse proteins in the cytoplasm and nucleus110.
Depending on the specific brain regions, cell types, and patholo-
gical conditions, the effect of O-GlcNAc modification in the brain
can be variable and may even be harmful in some cases. In
addition, another important issue researchers should address when
investigating O-GlcNAcylation is the reliable detection of
O-GlcNAcylated proteins, which is still challenging for several
reasons. First, since the donor substrate of O-GlcNAc modification,
UDP-GlcNAc, is produced by the sequential integration of nutrients,
including glucose, amino acids, fatty acids, and nucleotides, via HBP,
O-GlcNAcylation is highly sensitive to the metabolic states of cells in
living animals2,3,12. Second, even though O-GlcNAcylation itself is
abundant in the brain, each individual O-GlcNAc-modified protein is
generally present in low abundance33. Finally, O-GlcNAcylation is
labile and easily lost from peptides during the process of
dissociation111. Fortunately, however, recent progress in proteomics
and new emerging strategies in the detection of O-GlcNAcylation
have enabled us to overcome these aforementioned difficulties/
issues112. In addition, the development of single-cell isolation and
analysis can further provide detailed profiling of individual cell-
specific responses, ranging from gene expression to proteomics113.
Undoubtedly, this technology may greatly encourage the inter-
pretation of neuron type-specific and protein-specific effects of
O-GlcNAcylation in the near future.
In this review, we briefly described recent progress demonstrat-
ing the neuroprotective effects of O-GlcNAcylation in a variety of
neurodegenerative diseases. Our understanding of O-GlcNAcylation
in the brain continues to evolve at a rapid pace, but its practical
application for therapeutic goals is still in its infancy. Moving
forward, the utilization of advanced new technologies will allow us
to dissect the molecular alterations by O-GlcNAcylation that
determine disease-specific pathology and its alleviation in neuro-
degenerative diseases.
REFERENCES
1. Zachara, N. E. & Hart, G. W. Cell signaling, the essential role of O-GlcNAc! Bio-
chim. Biophys. Acta 1761, 599–617 (2006).
2. Hardiville, S. & Hart, G. W. Nutrient regulation of signaling, transcription, and cell
physiology by O-GlcNAcylation. Cell Metab. 20, 208–213 (2014).
3. Bond, M. R. & Hanover, J. A. A little sugar goes a long way: the cell biology of
O-GlcNAc. J. Cell Biol. 208, 869–880 (2015).
4. Bond, M. R. & Hanover, J. A. O-GlcNAc cycling: a link between metabolism and
chronic disease. Annu. Rev. Nutr. 33, 205–229 (2013).
5. Lewis, B. A. & Hanover, J. A. O-GlcNAc and the epigenetic regulation of gene
expression. J. Biol. Chem. 289, 34440–34448 (2014).
6. Torres, C. R. & Hart, G. W. Topography and polypeptide distribution of terminal
N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence
for O-linked GlcNAc. J. Biol. Chem. 259, 3308–3317 (1984).
7. Hanover, J. A., Cohen, C. K., Willingham, M. C. & Park, M. K. O-linked N-acet-
ylglucosamine is attached to proteins of the nuclear pore. Evidence for
cytoplasmic and nucleoplasmic glycoproteins. J. Biol. Chem. 262, 9887–9894
(1987).
8. Hart, G. W., Slawson, C., Ramirez-Correa, G. & Lagerlof, O. Cross talk between
O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and
chronic disease. Annu. Rev. Biochem. 80, 825–858 (2011).
9. Banerjee, P. S., Hart, G. W. & Cho, J. W. Chemical approaches to study
O-GlcNAcylation. Chem. Soc. Rev. 42, 4345–4357 (2013).
10. Wulff-Fuentes, E. et al. The human O-GlcNAcome database and meta-analysis.
Sci. Data. 8, 25 (2021).
11. Marshall, S., Bacote, V. & Traxinger, R. R. Discovery of a metabolic pathway
mediating glucose-induced desensitization of the glucose transport system.
Role of hexosamine biosynthesis in the induction of insulin resistance. J. Biol.
Chem. 266, 4706–4712 (1991).
12. Butkinaree, C., Park, K. & Hart, G. W. O-linked beta-N-acetylglucosamine (O-
GlcNAc): extensive crosstalk with phosphorylation to regulate signaling and
transcription in response to nutrients and stress. Biochim. Biophys. Acta 1800,
96–106 (2010).
13. Chatham, J. C., Zhang, J. & Wende, A. R. Role of O-linked N-acetylglucosamine
protein modification in cellular (Patho)physiology. Physiol. Rev. 101, 427–493
(2021).
14. Housley, M. P. et al. O-GlcNAc regulates FoxO activation in response to glucose.
J. Biol. Chem. 283, 16283–16292 (2008).
15. Erickson, J. R. et al. Diabetic hyperglycaemia activates CaMKII and arrhythmias
by O-linked glycosylation. Nature 502, 372–376 (2013).
16. Lu, S. et al. Hyperglycemia acutely increases cytosolic reactive oxygen species
via O-linked GlcNAcylation and CaMKII activation in mouse ventricular myo-
cytes. Circ. Res. 126, e80–e96 (2020).
17. Jiang, M. et al. Elevated O-GlcNAcylation promotes gastric cancer cells pro-
liferation by modulating cell cycle related proteins and ERK 1/2 signaling.
Oncotarget 7, 61390–61402 (2016).
18. Han, C. et al. O-GlcNAcylation of SIRT1 enhances its deacetylase activity and
promotes cytoprotection under stress. Nat. Commun. 8, 1491 (2017).
B.E. Lee et al.
7
Experimental & Molecular Medicine
19. Slawson, C. & Hart, G. W. O-GlcNAc signalling: implications for cancer cell biol-
ogy. Nat. Rev. Cancer 11, 678–684 (2011).
20. Dassanayaka, S. & Jones, S. P. O-GlcNAc and the cardiovascular system. Phar-
macol. Ther. 142, 62–71 (2014).
21. Slawson, C., Copeland, R. J. & Hart, G. W. O-GlcNAc signaling: a metabolic link
between diabetes and cancer? Trends Biochem. Sci. 35, 547–555 (2010).
22. Ferrer, C. M. et al. O-GlcNAcylation regulates cancer metabolism and survival
stress signaling via regulation of the HIF-1 pathway. Mol. Cell. 54, 820–831 (2014).
23. Gelinas, R. et al. AMPK activation counteracts cardiac hypertrophy by reducing
O-GlcNAcylation. Nat. Commun. 9, 374 (2018).
24. Gao, Y., Wells, L., Comer, F. I., Parker, G. J. & Hart, G. W. Dynamic O-glycosylation
of nuclear and cytosolic proteins: cloning and characterization of a neutral,
cytosolic beta-N-acetylglucosaminidase from human brain. J. Biol. Chem. 276,
9838–9845 (2001).
25. Okuyama, R. & Marshall, S. UDP-N-acetylglucosaminyl transferase (OGT) in brain
tissue: temperature sensitivity and subcellular distribution of cytosolic and
nuclear enzyme. J. Neurochem 86, 1271–1280 (2003).
26. O’Donnell, N., Zachara, N. E., Hart, G. W. & Marth, J. D. Ogt-dependent X-
chromosome-linked protein glycosylation is a requisite modification in somatic
cell function and embryo viability. Mol. Cell. Biol. 24, 1680–1690 (2004).
27. Keembiyehetty, C. et al. Conditional knock-out reveals a requirement for
O-linked N-Acetylglucosaminase (O-GlcNAcase) in metabolic homeostasis. J.
Biol. Chem. 290, 7097–7113 (2015).
28. Yang, Y. R. et al. O-GlcNAcase is essential for embryonic development and
maintenance of genomic stability. Aging Cell 11, 439–448 (2012).
29. Olivier-Van Stichelen, S., Wang, P., Comly, M., Love, D. C. & Hanover, J. A.
Nutrient-driven O-linked N-acetylglucosamine (O-GlcNAc) cycling impacts
neurodevelopmental timing and metabolism. J. Biol. Chem. 292, 6076–6085
(2017).
30. Su, C. & Schwarz, T. L. O-GlcNAc transferase is essential for sensory neuron
survival and maintenance. J. Neurosci. 37, 2125–2136 (2017).
31. Wang, A. C., Jensen, E. H., Rexach, J. E., Vinters, H. V. & Hsieh-Wilson, L. C. Loss of
O-GlcNAc glycosylation in forebrain excitatory neurons induces neurodegen-
eration. Proc. Natl Acad. Sci. USA 113, 15120–15125 (2016).
32. Lee, B. E. et al. O-GlcNAcylation regulates dopamine neuron function, survival
and degeneration in Parkinson disease. Brain 143, 3699–3716 (2020).
33. Cole, R. N. & Hart, G. W. Cytosolic O-glycosylation is abundant in nerve terminals.
J. Neurochem. 79, 1080–1089 (2001).
34. Vosseller, K. et al. O-linked N-acetylglucosamine proteomics of postsynaptic
density preparations using lectin weak affinity chromatography and mass
spectrometry. Mol. Cell Proteom. 5, 923–934 (2006).
35. Khidekel, N., Ficarro, S. B., Peters, E. C. & Hsieh-Wilson, L. C. Exploring the
O-GlcNAc proteome: direct identification of O-GlcNAc-modified proteins from
the brain. Proc. Natl Acad. Sci. USA 101, 13132–13137 (2004).
36. Taylor, E. W. et al. O-GlcNAcylation of AMPA receptor GluA2 is associated with a
novel form of long-term depression at hippocampal synapses. J. Neurosci. 34,
10–21 (2014).
37. Dias, W. B., Cheung, W. D., Wang, Z. & Hart, G. W. Regulation of calcium/cal-
modulin-dependent kinase IV by O-GlcNAc modification. J. Biol. Chem. 284,
21327–21337 (2009).
38. Rexach, J. E. et al. Dynamic O-GlcNAc modification regulates CREB-mediated
gene expression and memory formation. Nat. Chem. Biol. 8, 253–261 (2012).
39. Hwang, H. & Rhim, H. Acutely elevated O-GlcNAcylation suppresses hippo-
campal activity by modulating both intrinsic and synaptic excitability factors.
Sci. Rep. 9, 7287 (2019).
40. Ruan, H. B. et al. O-GlcNAc transferase enables AgRP neurons to suppress
browning of white fat. Cell 159, 306–317 (2014).
41. Lagerlof, O. et al. The nutrient sensor OGT in PVN neurons regulates feeding.
Science 351, 1293–1296 (2016).
42. Lagerlof, O., Hart, G. W. & Huganir, R. L. O-GlcNAc transferase regulates excita-
tory synapse maturity. Proc. Natl Acad. Sci. USA 114, 1684–1689 (2017).
43. Banerjee, P. S., Lagerlof, O. & Hart, G. W. Roles of O-GlcNAc in chronic diseases of
aging. Mol. Asp. Med. 51, 1–15 (2016).
44. Wheatley, E. G. et al. Neuronal O-GlcNAcylation improves cognitive function in
the aged mouse brain. Curr. Biol. 29, 3359–3369 e3354 (2019).
45. Rex-Mathes, M. et al. O-GlcNAc expression in developing and ageing mouse
brain. Biochimie 83, 583–590 (2001).
46. Fulop, N. et al. Aging leads to increased levels of protein O-linked N-acet-
ylglucosamine in heart, aorta, brain and skeletal muscle in Brown-Norway rats.
Biogerontology 9, 139 (2008).
47. White, C. W. 3rd et al. Age-related loss of neural stem cell O-GlcNAc promotes a
glial fate switch through STAT3 activation. Proc. Natl Acad. Sci. USA 117,
22214–22224 (2020).
48. Wang, Z. et al. Increasing O-GlcNAcylation is neuroprotective in young and aged
brains after ischemic stroke. Exp. Neurol. 339, 113646 (2021).
49. Love, D. C. et al. Dynamic O-GlcNAc cycling at promoters of Caenorhabditis
elegans genes regulating longevity, stress, and immunity. Proc. Natl Acad. Sci.
USA 107, 7413–7418 (2010).
50. Denzel, M. S. et al. Hexosamine pathway metabolites enhance protein quality
control and prolong life. Cell 156, 1167–1178 (2014).
51. Weimer, S. et al. D-Glucosamine supplementation extends life span of nema-
todes and of ageing mice. Nat. Commun. 5, 3563 (2014).
52. Lazarus, B. D., Love, D. C. & Hanover, J. A. O-GlcNAc cycling: implications for
neurodegenerative disorders. Int. J. Biochem. Cell Biol. 41, 2134–2146 (2009).
53. Ma, X., Li, H., He, Y. & Hao, J. The emerging link between O-GlcNAcylation and
neurological disorders. Cell Mol. Life Sci. 74, 3667–3686 (2017).
54. Wani, W. Y., Chatham, J. C., Darley-Usmar, V., McMahon, L. L. & Zhang, J.
O-GlcNAcylation and neurodegeneration. Brain Res. Bull. 133, 80–87 (2017).
55. Ryan, P. et al. O-GlcNAc modification protects against protein misfolding and
aggregation in neurodegenerative disease. ACS Chem. Neurosci. 10, 2209–2221
(2019).
56. Arnold, C. S. et al. The microtubule-associated protein tau is extensively mod-
ified with O-linked N-acetylglucosamine. J. Biol. Chem. 271, 28741–28744 (1996).
57. Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W. & Gong, C. X. O-GlcNAcylation
regulates phosphorylation of tau: a mechanism involved in Alzheimer’s disease.
Proc. Natl Acad. Sci. USA 101, 10804–10809 (2004).
58. Morris, M. et al. Tau post-translational modifications in wild-type and human
amyloid precursor protein transgenic mice. Nat. Neurosci. 18, 1183–1189 (2015).
59. Yuzwa, S. A. et al. Increasing O-GlcNAc slows neurodegeneration and stabilizes
tau against aggregation. Nat. Chem. Biol. 8, 393–399 (2012).
60. Breijyeh, Z. & Karaman, R. Comprehensive review on Alzheimer’s disease: causes
and treatment. Molecules 25, 5789 (2020).
61. Liu, F. et al. Reduced O-GlcNAcylation links lower brain glucose metabolism and
tau pathology in Alzheimer’s disease. Brain 132, 1820–1832 (2009).
62. Balana, A. T. et al. O-GlcNAc modification of small heat shock proteins enhances
their anti-amyloid chaperone activity. Nat. Chem. 13, 441–450 (2021).
63. Park, J. et al. O-GlcNAcylation ameliorates the pathological manifestations of
Alzheimer’s disease by inhibiting necroptosis. Sci. Adv. 7, eabd3207 (2021).
64. Iqbal, K. et al. Tau pathology in Alzheimer disease and other tauopathies. Bio-
chim. Biophys. Acta 1739, 198–210 (2005).
65. Kopeikina, K. J., Hyman, B. T. & Spires-Jones, T. L. Soluble forms of tau are toxic in
Alzheimer’s disease. Transl. Neurosci. 3, 223–233 (2012).
66. Yuzwa, S. A. et al. A potent mechanism-inspired O-GlcNAcase inhibitor that
blocks phosphorylation of tau in vivo. Nat. Chem. Biol. 4, 483–490 (2008).
67. Lewis, J. et al. Neurofibrillary tangles, amyotrophy and progressive motor dis-
turbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25,
402–405 (2000).
68. Busche, M. A. & Hyman, B. T. Synergy between amyloid-beta and tau in Alz-
heimer’s disease. Nat. Neurosci. 23, 1183–1193 (2020).
69. Kim, C. et al. O-linked beta-N-acetylglucosaminidase inhibitor attenuates beta-
amyloid plaque and rescues memory impairment. Neurobiol. Aging 34, 275–285
(2013).
70. Shah, S. et al. Nicastrin functions as a gamma-secretase-substrate receptor. Cell
122, 435–447 (2005).
71. Medina, M. An overview on the clinical development of Tau-based therapeutics.
Int. J. Mol. Sci. 19, 1160 (2018).
72. McColgan, P. & Tabrizi, S. J. Huntington’s disease: a clinical review. Eur. J. Neurol.
25, 24–34 (2018).
73. Walker, F. O. Huntington’s disease. Lancet 369, 218–228 (2007).
74. Tabrizi, S. J., Flower, M. D., Ross, C. A. & Wild, E. J. Huntington disease: new
insights into molecular pathogenesis and therapeutic opportunities. Nat. Rev.
Neurol. 16, 529–546 (2020).
75. Stephanie, O. V.-S. The human O-GlcNAcome database. figshare. https://figshare.
com/articles/dataset/The_human_O-GlcNAcome_database/12443495 (2020).
76. Kumar, A. et al. Decreased O-linked GlcNAcylation protects from cytotoxicity
mediated by huntingtin exon1 protein fragment. J. Biol. Chem. 289,
13543–13553 (2014).
77. Gasset-Rosa, F. et al. Polyglutamine-expanded Huntingtin exacerbates age-
related disruption of nuclear integrity and nucleocytoplasmic transport. Neuron
94, 48–57 e44 (2017).
78. Tang, B. et al. Gene expression profiling of R6/2 transgenic mice with different
CAG repeat lengths reveals genes associated with disease onset and progres-
sion in Huntington’s disease. Neurobiol. Dis. 42, 459–467 (2011).
79. Menalled, L. B. et al. Comprehensive behavioral and molecular characterization
of a new knock-in mouse model of Huntington’s disease: zQ175. PLoS ONE 7,
e49838 (2012).
80. Grima, J. C. et al. Mutant Huntingtin disrupts the nuclear pore complex. Neuron
94, 93–107 e106 (2017).
81. Zhu, Y. et al. Post-translational O-GlcNAcylation is essential for nuclear pore integrity
and maintenance of the pore selectivity filter. J. Mol. Cell Biol. 8, 2–16 (2016).
B.E. Lee et al.
8
Experimental & Molecular Medicine
82. Masrori, P. & Van Damme, P. Amyotrophic lateral sclerosis: a clinical review. Eur.
J. Neurol. 27, 1918–1929 (2020).
83. Mejzini, R. et al. ALS genetics, mechanisms, and therapeutics: where are we
now? Front. Neurosci. 13, 1310 (2019).
84. Morgan, S. & Orrell, R. W. Pathogenesis of amyotrophic lateral sclerosis. Br. Med.
Bull. 119, 87–98 (2016).
85. Shan, X., Vocadlo, D. J. & Krieger, C. Reduced protein O-glycosylation in the
nervous system of the mutant SOD1 transgenic mouse model of amyotrophic
lateral sclerosis. Neurosci. Lett. 516, 296–301 (2012).
86. Xiao, S., McLean, J. & Robertson, J. Neuronal intermediate filaments and ALS: a
new look at an old question. Biochim. Biophys. Acta 1762, 1001–1012 (2006).
87. Lobsiger, C. S., Garcia, M. L., Ward, C. M. & Cleveland, D. W. Altered axonal
architecture by removal of the heavily phosphorylated neurofilament tail
domains strongly slows superoxide dismutase 1 mutant-mediated ALS. Proc.
Natl Acad. Sci. USA 102, 10351–10356 (2005).
88. Dong, D. L., Xu, Z. S., Hart, G. W. & Cleveland, D. W. Cytoplasmic O-GlcNAc
modification of the head domain and the KSP repeat motif of the neurofilament
protein neurofilament-H. J. Biol. Chem. 271, 20845–20852 (1996).
89. Ludemann, N. et al. O-glycosylation of the tail domain of neurofilament protein
M in human neurons and in spinal cord tissue of a rat model of amyotrophic
lateral sclerosis (ALS). J. Biol. Chem. 280, 31648–31658 (2005).
90. Chen, Y. I., Wei, P. C., Hsu, J. L., Su, F. Y. & Lee, W. H. NPGPx (GPx7): a novel
oxidative stress sensor/transmitter with multiple roles in redox homeostasis. Am.
J. Transl. Res. 8, 1626–1640 (2016).
91. Hsieh, Y. L. et al. NPGPx-mediated adaptation to oxidative stress protects motor
neurons from degeneration in aging by directly modulating O-GlcNAcase. Cell
Rep. 29, 2134–2143 e2137 (2019).
92. Cohen, T. J., Lee, V. M. & Trojanowski, J. Q. TDP-43 functions and pathogenic
mechanisms implicated in TDP-43 proteinopathies. Trends Mol. Med. 17,
659–667 (2011).
93. Saberi, S., Stauffer, J. E., Schulte, D. J. & Ravits, J. Neuropathology of amyotrophic
lateral sclerosis and its variants. Neurol. Clin. 33, 855–876 (2015).
94. Zhao, M. J. et al. O-GlcNAcylation of TDP-43 suppresses proteinopathies and
promotes TDP-43’s mRNA splicing activity. EMBO Rep. 22, e51649 (2021).
95. Kalia, L. V. & Lang, A. E. Parkinson’s disease. Lancet 386, 896–912 (2015).
96. Dauer, W. & Przedborski, S. Parkinson’s disease: mechanisms and models.
Neuron 39, 889–909 (2003).
97. Davie, C. A. A review of Parkinson’s disease. Br. Med. Bull. 86, 109–127 (2008).
98. Dexter, D. T. & Jenner, P. Parkinson disease: from pathology to molecular disease
mechanisms. Free Radic. Biol. Med. 62, 132–144 (2013).
99. Schapira, A. H. V., Chaudhuri, K. R. & Jenner, P. Non-motor features of Parkinson
disease. Nat. Rev. Neurosci. 18, 435–450 (2017).
100. Smith, Y., Wichmann, T., Factor, S. A. & DeLong, M. R. Parkinson’s disease ther-
apeutics: new developments and challenges since the introduction of levodopa.
Neuropsychopharmacol. 37, 213–246 (2012).
101. Spillantini, M. G. et al. Alpha-synuclein in Lewy bodies. Nature 388, 839–840
(1997).
102. Kim, W. S., Kagedal, K. & Halliday, G. M. Alpha-synuclein biology in Lewy body
diseases. Alzheimers Res. Ther. 6, 73 (2014).
103. Bras, I. C. & Outeiro, T. F. Alpha-synuclein: mechanisms of release and pathology
progression in synucleinopathies. Cells 10, 375 (2021).
104. Zhang, J., Li, X. & Li, J. D. The roles of post-translational modifications on alpha-
synuclein in the pathogenesis of Parkinson’s diseases. Front. Neurosci. 13, 381
(2019).
105. Wang, Z. et al. Enrichment and site mapping of O-linked N-acetylglucosamine
by a combination of chemical/enzymatic tagging, photochemical cleavage, and
electron transfer dissociation mass spectrometry. Mol. Cell Proteom. 9, 153–160
(2010).
106. Marotta, N. P. et al. O-GlcNAc modification blocks the aggregation and toxicity
of the protein alpha-synuclein associated with Parkinson’s disease. Nat. Chem. 7,
913–920 (2015).
107. Levine, P. M. et al. alpha-Synuclein O-GlcNAcylation alters aggregation and
toxicity, revealing certain residues as potential inhibitors of Parkinson’s disease.
Proc. Natl Acad. Sci. USA 116, 1511–1519 (2019).
108. Galesic, A. et al. Comparison of N-acetyl-glucosamine to other monosaccharides
reveals structural differences for the inhibition of alpha-synuclein aggregation.
ACS Chem. Biol. 16, 14–19 (2021).
109. Tavassoly, O., Yue, J. & Vocadlo, D. J. Pharmacological inhibition and knockdown
of O-GlcNAcase reduces cellular internalization of alpha-synuclein preformed
fibrils. FEBS J. 288, 452–470 (2021).
110. Yang, X. & Qian, K. Protein O-GlcNAcylation: emerging mechanisms and func-
tions. Nat. Rev. Mol. Cell Biol. 18, 452–465 (2017).
111. Cecioni, S. & Vocadlo, D. J. Tools for probing and perturbing O-GlcNAc in cells
and in vivo. Curr. Opin. Chem. Biol. 17, 719–728 (2013).
112. Xu, S., Sun, F., Tong, M. & Wu, R. MS-based proteomics for comprehensive
investigation of protein O-GlcNAcylation. Mol. Omics 17, 186–196 (2021).
113. Hu, P., Zhang, W., Xin, H. & Deng, G. Single cell isolation and analysis. Front. Cell
Dev. Biol. 4, 116 (2016).
ACKNOWLEDGEMENTS
This research was supported by the Basic Science Research Program through the
National Research Foundation of Korea (NRF) funded by the Ministry of Science and
ICT (2020R1A2C1005492 and 2021R1A4A1031644 to J.-I.K.). This research was also
supported by the Asan Foundation Biomedical Research Fellowship (B.E.L.).
AUTHOR CONTRIBUTIONS
Conceptualization, B.E.L. and J.-I.K.; original draft preparation, B.E.L. and J.-I.K.; review
and editing, P.-G.S. and J.-I.K.; supervision, J.-I.K. All authors have read and agreed to
the current version of the manuscript.
COMPETING INTERESTS
The authors declare no competing interests.
ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Jae-Ick Kim.
Reprints and permission information is available at http://www.nature.com/
reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2021
B.E. Lee et al.
9
Experimental & Molecular Medicine
